AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
2.040
+0.020 (0.99%)
May 16, 2025, 10:29 AM - Market open
Company Description
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis.
The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
AbCellera Biologics Inc.
| Country | Canada |
| Founded | 2012 |
| IPO Date | Dec 11, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 596 |
| CEO | Carl Hansen |
Contact Details
Address: 150 West 4th Ave Vancouver, BC V5Y 1G6 Canada | |
| Phone | 604 559 9005 |
| Website | abcellera.com |
Stock Details
| Ticker Symbol | ABCL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001703057 |
| CUSIP Number | 00288U106 |
| ISIN Number | CA00288U1066 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carl L.G. Hansen Ph.D. | Chief Executive Officer, President and Chairperson |
| Andrew Booth M.B.A. | Chief Financial Officer |
| Tryn T. Stimart Esq., J.D., M.Sc. | Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary and Privacy Officer |
| Dr. Veronique Lecault Ph.D. | Chief Technology Officer and Director |
| Tiffany Chiu B.Sc., Ph.D. | Vice President of Communications |
| Graham Craig M.Sc. | Director of Corporate Development |
| Murray McCutcheon Ph.D. | Senior Vice President of Partnering |
| Neil Aubuchon B.A., M.B.A. | Chief Commercial Officer |
| Adam Clarke M.A.I.C.D., Ph.D. | Senior Vice President of Discovery |
| Paul Colussi Ph.D. | Site Head and Vice President of Australia |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2025 | 8-K | Current Report |
| May 13, 2025 | 8-K | Current Report |
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Feb 27, 2025 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2025 | 10-K | Annual Report |